Generics market in Greece: The pharmaceutical industry's beliefs

Health Policy

Volumn 79, Issue 1, 2006, Pages 35-48

  Geitona, Mary ^a   Zavras, Dimitrios ^b   Hatzikou, Magda ^a   Kyriopoulos, John ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

Author keywords

Brand name drugs' substitution; Generic medication; Generics market; Greek pharmaceutical industry; Health insurance; Pharmacoeconomic submissions

Indexed keywords

GENERIC DRUG;

ADVERTIZING; ARTICLE; BINOMIAL DISTRIBUTION; BIOEQUIVALENCE; DESCRIPTIVE RESEARCH; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC EVALUATION; FISHER EXACT TEST; HEALTH ECONOMICS; OUTCOME ASSESSMENT; POLICY; QUESTIONNAIRE; REIMBURSEMENT; SAFETY; SOCIAL INSURANCE; SOCIOECONOMICS; STATISTICAL ANALYSIS;

ADMINISTRATIVE PERSONNEL; ADVERTISING; ADVERTISING AS TOPIC; ATTITUDE OF HEALTH PERSONNEL; COST CONTROL; COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; DRUG COSTS; DRUG INDUSTRY; DRUG INFORMATION SERVICES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUGS, GENERIC; ECONOMIC COMPETITION; GOVERNMENT REGULATION; GREECE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MARKETING; NATIONAL HEALTH PROGRAMS; NEGATIVISM; PATIENT EDUCATION; PATIENT EDUCATION AS TOPIC; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; REIMBURSEMENT MECHANISMS; SAFETY; SOCIETIES, PHARMACEUTICAL; THERAPEUTIC EQUIVALENCY;

EID: 33748745207     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2005.11.004     Document Type: Article

References (32)

1. Mossialos E. Regulating expenditure on medicines in European Union countries. In: Saltman R., et al. (Ed). Critical challenges for health care reform in Europe (1999), Open University Press, Berkshire 261-286
2. Maynard A. The regulation of the pharmaceutical industry. In: Drummond M.F., and Maynard A. (Eds). Purchasing and providing cost effective health care (1993), Churchill Livingstone, Edinburgh 234-242
3. Lexchin J. Pharmaceuticals, patents, and politics. International Journal of Health Services 23 1 (1993) 147-160
4. Mossialos E., and Mrazek M. Entrepreneurial behaviour in pharmaceutical markets and the effects of regulation. In: Saltmant R., et al. (Ed). Regulating entrepreneurial behaviour in European health care systems (2002), Open University Press, Buckingham 61-86
5. McGuire A., Drummond M., and Rutten F. Reimbursement of pharmaceuticals in the European Union. In: Mossialos E., et al. (Ed). Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. European Observatory on Health Systems and Policies Series (2004), Open University Press, Berkshire 130-143
6. Mossialos E., Walley T., and Mrazek M. Regulating pharmaceuticals in Europe: an overview. In: Mossialos E., et al. (Ed). Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. European Observatory on Health Systems and Policies Series (2004), Open University Press, Berkshire 1-37
7. Kanavos P. Pharmaceutical pricing and reimbursement in Europe. SCRIP reports. PBJ Publications; 2002.
8. Lopez-Casasnovas G., and Puig-Junou J. Review of the literature on reference pricing. Health Policy 54 (2000) 87-123
9. McLaughlin P.R. Reference-based pricing of prescription drugs. Canadian Journal of Cardiology 13 1 (1997) 31-32
10. Ansa E.I., Agudo P.C., Artazcoz S.M., and Carnicero G.J. Usefulness of prescription of generic drugs for cost containment in pharmaceutics. Analysis in the Community of Navarra. Atencion Primaria 17 6 (1996) 411-414
11. Nicol D. Balancing access to pharmaceuticals with patent rights. Monash Bioethics Review 22 2 (2003) 50-62
12. Anis A.H., Guh D.P., and Woolcott J. Lowering generic drug prices: less regulation equals more competition. Medical Care 41 1 (2003) 135-141
13. http://www.fda.gov/cder/ogd
14. Garattini L., and Tediosi F. Comparative analysis of generic markets in five European countries. Health Policy 51 (2000) 149-162
15. Kessler D., Rose J.L., Temple R.J., Shapiro R., and Griffin J.P. Therapeutic-class wars: drug promotion in a competitive marketplace. The New England Journal of Medicine 331 (1994) 1350-1354
16. Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy 68 1 (2004) 47-54
17. Bouvenot G., Villani P., and Bouvenot J. Generic drugs in the medical-economic context of drug prescriptions. Presse Medicale 31 24 (2002) 1109-1114
18. Menon D. Pharmaceutical cost control in Canada: does it work?. Health Affairs 20 3 (2001) 1-13
19. Paraponaris A., Verger P., Desquins B., Villani P., Bouvenot G., Rochaix L., et al. Delivering generics without regulatory incentives? Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names. Health Policy 70 1 (2004) 23-32
20. Fisher M.A., and Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Services Research 38 4 (2003) 1051-1063
21. Kontozamanis V., and Koussoulakou H. Regulatory framework of pharmaceutical market. In: Geitona M. (Ed). Economic evaluation in health care: pharmacoeconomics and decision making (2004), University of Thessaly, Volos 103-124
22. Mossialos E., Allin S., and Davaki K. Analysing the Greek health system: a tale of fragmentation and inertia. Health Economics 14 (2005) S151-S168
23. Geitona M., Kyriopoulos J., Zavras D., and Karamouzis J. Market share and characteristics of generic drugs in Greece. Value in Health 6 6 (2003) 717
24. Koussoulakou H., and Fragoulakis V. Pharmaceutical market in Greece (2004), Foundation for Economic and Industrial Research (IOBE), Athens
25. IMS, 2003, http://www.imshealth.com (IMS health data 2003).
26. Athens: Institute of Pharmaceutical Research and Technology (IFET); 2005 [http://www.ifet.gr/site_phar/origin.htm].
27. The pharmaceutical market in Greece: facts and figures. Athens: Hellenic Association of Pharmaceutical Companies (SFEE); 2005 [http://www.sfee.gr/download/english/1120/index.html].
28. Casado B.S., Sagardui J.K., and Lacalle M. The substitution of generic for brand medicines in family medical clinics. Atencion Primaria 30 6 (2002) 343-347
29. Morgan S., Kozyrskyj A., Metge C., Roos N., and Dahl M. Pharmaceuticals: therapeutic interchange and pricing policies (2003), Manitoba Centre for Health Policy, University of Manitoba
30. Vallee J.P. Generic drugs and the rights of substitution. Presse Medicale 28 10 (1999) 535-538
31. Gonzalez Hernando S., Gonzalez Mieres C., and Diaz Martin A.M. Intention of purchasing generic prescription drugs on the part of consumers in Asturias, Spain. Revista Espanola de Salud Publica 77 6 (2003) 691-699
32. Tilson L., McGowan B., Ryan M., and Barry M. Generic drug utilisation on the General Medical Services (GMS) scheme in 2001. Irish Medical Journal 96 6 (2003) 176-179